Original ResearchPublished 12 October 2026Reporting signals of selected extrapyramidal adverse events with four newer second-generation antipsychotics: a disproportionality analysis of FAERS spontaneous reportsPan Ma · Qin Xiao · Yunpei Zhao · Xin Zhang · Huan Ma · Dan Chen · Linli XieFrontiers in Pharmacologydoi 10.3389/fphar.2026.1921943
Original ResearchPublished 9 October 2026Metformin-associated diarrhea in FAERS: a structured pharmacovigilance study with long-term temporal consistency assessmentShida Chen · Chengan XuFrontiers in Pharmacologydoi 10.3389/fphar.2026.1902348
Original ResearchPublished 9 October 2026Real-world pharmacovigilance analysis and cross-database consistency assessment of resmetirom-related adverse events using FAERS and VigiAccessYali Zhong · Cong Hou · Lingzuo Zhao · Xiaobin LuoFrontiers in Pharmacologydoi 10.3389/fphar.2026.1898840
Original ResearchPublished 9 October 2026Adverse reactions of immune checkpoint inhibitors combined with acetaminophen/non-steroidal anti-inflammatory drugs (NSAIDs): a pharmacovigilance analysis of drug–drug interactionsXiayang Ren · Lihui Xue · Yanfeng Wang · Jian XiaoFrontiers in Pharmacologydoi 10.3389/fphar.2026.1833275
Original ResearchPublished 2 October 2026Safety of lecanemab in real-world patients with Alzheimer’s disease: a prospective, observational case series supported by FAERS signal analysisHaixia Ji · Yang Yang · Xingqi Wu · Erhao BaoFrontiers in Neuroinformaticsdoi 10.3389/fninf.2026.1977226
Original ResearchPublished 28 September 2026Two decades of prescription opioid-related cardiovascular safety signals: a FAERS-based pharmacovigilance study using machine learningLi Ma · Johnna Berryhill · John Ihrie · Ru Chen · Beverly Lyn-Cook · Paul Rogers · Weigong Ge · Ningning Wu · Huixiao Hong · Weida Tong · Wen ZouFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2026.1898403
Original ResearchPublished 4 September 2026Global patterns and trends in spontaneous reporting systems: VigiBase, FAERS, VAERS, and JADERNikola Panajotovikj · Jordi MestresFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2026.1919822
Original ResearchPublished 10 June 2026Comprehensive pharmacovigilance assessment of pairwise drug–drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugsIssei Kazume · Kenji Onda · Sachiko Tanaka · Takashi Yokokawa · Kenichi SuzukiFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2026.1827098
Original ResearchPublished 5 June 2026Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian analysis based on the FAERS databaseHongxin Li · Jun Wang · Lingjun Kong · Qingwang Wei · Chengwu Shen · Dongna ZouFrontiers in Antibioticsdoi 10.3389/frabi.2026.1781902
Original ResearchPublished 12 December 2025A real-world disproportionality analysis of roflumilast using the US food and drug administration adverse event reporting system dataBaiqing Huang · Yirou Ma · Wenli Wang · Shaorui Gu · Xisheng WangFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1721656
ReviewPublished 26 November 2025Discrepancies in regulations in post-marketing safety surveillance of drug-device combination products in the EU and US: a reviewJoan D’souza · Mukesh Nandave · Ruth BlöchlingerFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1609455
